Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Biomarkers of response to advanced prostate cancer therapy.
Iacovelli R, Ciccarese C, Schinzari G, Rossi E, Maiorano BA, Astore S, D'Angelo T, Cannella A, Pirozzoli C, Teberino MA, Pierconti F, Martini M, Tortora G. Iacovelli R, et al. Among authors: cannella a. Expert Rev Mol Diagn. 2020 Feb;20(2):195-205. doi: 10.1080/14737159.2020.1707669. Epub 2020 Jan 27. Expert Rev Mol Diagn. 2020. PMID: 31986925 Review.
Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib.
Iacovelli R, Ciccarese C, Maruzzo M, Atzori F, Galli L, Scagliarini S, Massari F, Verzoni E, Cannella A, Maratta MG, Caserta C, Bimbatti D, Deppieri FM, Dessi M, Paolieri F, Riccardi F, Bracarda S, De Giorgi U, Basso U, Tortora G, Procopio G. Iacovelli R, et al. Among authors: cannella a. Clin Genitourin Cancer. 2022 Oct;20(5):498.e1-498.e9. doi: 10.1016/j.clgc.2022.06.006. Epub 2022 Jun 9. Clin Genitourin Cancer. 2022. PMID: 35768316
PTEN Loss as a Predictor of Tumor Heterogeneity and Poor Prognosis in Patients With EGFR-mutant Advanced Non-small-cell Lung Cancer Receiving Tyrosine Kinase Inhibitors.
Ferrara MG, Martini M, D'Argento E, Forcella C, Vita E, Di Noia V, Sperduti I, Bilotta M, Ribelli M, Damiano P, Cannella A, Stefani A, Pilotto S, Carbone C, Piro G, Milella M, Tortora G, Bria E. Ferrara MG, et al. Among authors: cannella a. Clin Lung Cancer. 2021 Jul;22(4):351-360. doi: 10.1016/j.cllc.2020.12.008. Epub 2021 Feb 6. Clin Lung Cancer. 2021. PMID: 33558194
Blood serum amyloid A as potential biomarker of pembrolizumab efficacy for patients affected by advanced non-small cell lung cancer overexpressing PD-L1: results of the exploratory "FoRECATT" study.
Di Noia V, D'Argento E, Pilotto S, Vita E, Ferrara MG, Damiano P, Ribelli M, Cannella A, Virtuoso A, Fattorossi A, Ceresoli GL, Milella M, Beretta GD, Tortora G, Bria E. Di Noia V, et al. Among authors: cannella a. Cancer Immunol Immunother. 2021 Jun;70(6):1583-1592. doi: 10.1007/s00262-020-02788-1. Epub 2020 Nov 24. Cancer Immunol Immunother. 2021. PMID: 33231726 Free PMC article. Clinical Trial.
Combination therapy with imiquimod and 5-fluorouracil cream for the treatment of actinic keratoses, a prospective open-label nonrandomized uncontrolled pilot trial.
Maxwell Regester R, Cannella AC, Hirz J, Sayles B, Schlange S, Rau A, Sayles HR, Griess AJ. Maxwell Regester R, et al. Among authors: cannella ac. J Am Acad Dermatol. 2024 Feb 3:S0190-9622(24)00214-7. doi: 10.1016/j.jaad.2024.01.065. Online ahead of print. J Am Acad Dermatol. 2024. PMID: 38316257 No abstract available.
68 results